Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.91
  • Today's Change-0.02 / -2.15%
  • Shares traded1.14m
  • 1 Year change-80.00%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 08:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Brii Biosciences Ltd is a biotechnology company based in China and the United States principally engaged in developing therapies for infectious diseases. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The Company is also developing therapies for COVID-19 and other diseases.

  • Revenue in HKD (TTM)668.81k
  • Net income in HKD-189.51m
  • Incorporated2017
  • Employees128.00
  • Location
    Brii Biosciences Ltd3rd Floor, Building 7Zhongguancun Dongsheng, InternationalNo. 1 North Yongtaizhuang Road, HaidianBEIJING 100192ChinaCHN
  • Websitehttps://www.briibio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kintor Pharmaceutical Ltd0.00-702.48m375.90m290.00--0.2616-----1.75-1.750.003.210.000.00--0.00-35.76---43.09----------2.69--0.1957---100.00---13.33------
Uni-Bio Science Group Ltd494.67m63.27m474.60m340.007.752.186.100.95940.00990.00990.07770.03531.722.6312.381,336,949.0022.06-13.4630.37-17.3678.6881.0612.79-13.992.04113.290.0824--24.5922.99296.58--1.74--
Clover Biopharmaceuticals Ltd278.58k-721.05m538.23m764.00--17.35--1,932.04-0.7099-0.70990.00020.02390.000060.00020.0126364.64-16.04---40.13--21.40---258,830.30--0.6913-6.950.9411------59.25------
Tianda Pharmaceuticals Ltd-100.00bn-100.00bn580.51m820.00--0.965----------0.2798------------------------1.10--0.1488--------------
Genor Biopharma Holdings Ltd14.07m-649.45m594.19m222.00--0.3488--42.24-1.28-1.280.02773.350.00610.00490.162953,279.03-28.10---31.48--98.49---4,614.84--6.51--0.021------15.60------
Pak Fah Yeow International Ltd217.41m88.16m638.86m99.007.250.84296.682.940.28290.28290.69762.430.25032.6820.722,288,547.0010.152.3910.812.5279.0378.8640.5515.055.03--0.0072136.165.28-3.76-21.56-21.82-36.22-13.57
Brii Biosciences Ltd668.81k-189.51m678.56m128.00--0.2006--1,014.58-0.2605-0.26050.00094.640.0002----5,225.10-5.60---5.84-------29,881.69------0.001---98.80--63.90------
Antengene Corporation Ltd72.96m-629.99m681.64m201.00--0.5481--9.34-1.02-1.020.11861.840.03580.97733.41362,969.90-30.91-53.57-36.46-58.9481.74---863.51-1,987.016.43--0.1491---57.97--3.38------
Fusen Pharmaceutical Co Ltd718.22m-12.05m712.46m1.12k--1.0727.200.992-0.016-0.0160.95250.88930.52353.207.84619,692.50-0.87943.33-1.636.0548.9652.20-1.688.900.61641.920.32114.2827.511.67-307.90--26.63--
Lee's Pharmaceutical Holdings Ltd1.10bn38.94m712.49m1.06k18.300.36097.220.64990.06610.06611.863.350.3571.578.31994,818.501.2915.771.6721.0757.9964.273.6241.780.54175.960.09635.25-2.614.10-97.42-26.09-4.38-28.09
Jbm (Healthcare) Ltd610.30m97.99m717.38m258.007.920.76464.821.180.10870.10870.67861.120.44065.884.102,000,994.007.563.339.044.9347.7045.9717.1710.971.4522.150.121113.8128.1114.51131.906.14-5.09--
JW (Cayman) Therapeutics Co Ltd188.46m-832.49m751.62m398.00--0.4112--3.99-2.02-2.020.45794.430.07041.8865.54473,506.60-31.11-39.77-35.21-44.0050.74---441.74-1,316.813.90-11.830.1592--19.32--9.23------
Sirnaomics Ltd0.00-660.15m784.36m180.00--1.23-----8.68-8.680.007.280.00----0.00-55.22---57.51--------------0.3655------58.56------
Zhaoke Ophthalmology Ltd12.25m-520.38m857.44m321.00--0.3533--69.98-0.9582-0.95820.02264.440.0044--0.411141,819.99-18.76---20.18--89.83---4,246.90--6.89-86.630.0807------80.88------
Transcenta Holding Limited125.98m-477.29m916.39m318.00--0.6661--7.27-1.14-1.140.30063.150.05344.094.55393,679.50-20.21---26.51--23.17---378.87--1.56-51.370.2621--102.80--76.29------
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd911.63m240.86m980.44m928.004.07--7.971.080.42990.42991.63--------1,107,696.00--8.64--11.4870.1581.7126.4222.22--149.92--12.2019.305.4535.096.04-20.57--
Data as of Mar 28 2024. Currency figures normalised to Brii Biosciences Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

9.51%Per cent of shares held by top holders
HolderShares% Held
Invesco Advisers, Inc.as of 10 Feb 202333.75m4.63%
E Fund Management Co., Ltd.as of 30 Jun 202322.80m3.13%
UBS Asset Management (Hong Kong) Ltd.as of 31 Jan 20245.97m0.82%
Bosera Asset Management Co., Ltd.as of 31 Dec 20225.67m0.78%
Xinyuan Asset Management Co., Ltd.as of 30 Jun 2023697.50k0.10%
SSgA Funds Management, Inc.as of 07 Mar 2024276.50k0.04%
American Century Investment Management, Inc.as of 07 Mar 2024111.50k0.02%
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 202362.00k0.01%
Truvalue Asset Management Co. Ltd.as of 30 Jun 20235.50k0.00%
Da Cheng Fund Management Co., Ltd.as of 31 Dec 20222.00k0.00%
More ▼
Data from 30 Jun 2023 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.